Objective. To perform a genome-wide DNA methylation study to identify DNA methylation changes in osteoarthritic (OA) cartilage tissue.
Osteoarthritis (OA) is a chronic, debilitating musculoskeletal disease characterized by progressive loss of function of both load-bearing and non-loadbearing joints, leading to significant pain and functional limitation. Although a hallmark of OA is loss of hyaline cartilage leading to joint space narrowing, other articular tissues and processes have been implicated, including synovial inflammation and subchondral bone remodeling. An unrecognized epidemic, OA is the leading cause of chronic disability in the US, affecting 40% of US adults age Ͼ70 years (1) . Indeed, the risk of disability resulting from knee or hip OA is equivalent to that resulting from cardiovascular disease (2) . Recent estimates place the annual cost of OA at $128 billion in the US, representing nearly 1% of gross domestic product (3) . Alarmingly, the prevalence of severe OA requiring joint replacement is increasing at a rate that exceeds expected increases due to obesity and aging (4) .
Unlike many other rheumatic diseases, relatively little is known about the pathophysiology of OA. Consequently, treatment options remain diminutive, consisting principally of analgesic agents and viscosupplementation. Remarkably, although the incidence of OA is 400-fold higher than that of rheumatoid arthritis (RA) (5) , there have been no disease-modifying agents approved for the treatment of OA. More must be done to understand the mechanisms involved in the development and progression of OA to move the field toward novel therapeutic strategies.
The pathogenesis of OA involves the interplay of 3 major factors: genetic predisposition, aging, and the environment (6) . Genome-wide association studies have identified surprisingly few candidate genetic susceptibility loci, the majority of which are within either structural genes or cellular signaling pathways (7) (8) (9) . Several studies have recently implicated epigenetic dysregulation as a contributor to OA pathology. Epigenetics, defined as heritable changes in gene expression that occur in the absence of mutations of underlying genomic DNA, is a common mechanism whereby organisms alter gene expression in response to both external and internal environmental cues. Epigenetic regulation occurs by a few common mechanisms, including genomic DNA methylation, alterations of histone side chains resulting in chromatin conformational change, and noncoding RNA feedback. Epigenetic dysregulation leading to inappropriate gene expression or silencing has been shown to play an important role in several rheumatic diseases, such as systemic lupus erythematosus (10) (11) (12) and RA (13) (14) (15) .
The most widely studied epigenetic control mechanism is DNA methylation. The addition of methyl groups to the 5Ј position of cytosine in fully differentiated tissues most commonly occurs in CpG dinucleotides, mediated by a variety of DNA methyltransferases. Methylation of certain regulatory regions is of particular transcriptional relevance, most commonly within the 5Ј-untranslated region (5Ј-UTR) or 5Ј-promoter region upstream of a target gene or located near or within CpG-enriched regions known as CpG islands. Methylated cytosines within these areas tend to be transcriptionally repressive, whereas unmethylated cytosines are permissive for gene expression. To date, few studies have been undertaken to examine the role of epigenetics in OA, but they have proven quite fruitful. Candidate gene methylation analyses in OA cartilage have identified significant alterations in DNA methylation signatures of the matrix metalloproteinases (MMPs) MMP3, MMP6, MMP9, MMP13 (16) , and ADAMTS4 (17) , and, curiously, the obesity-and inflammation-linked leptin gene (18) . A recent report described a genome-wide DNA methylation analysis that examined the status of ϳ27,000 CpG sites in OA knee cartilage compared to normal control cartilage and identified a number of differentially methylated CpG sites as well as a cluster of cases that appeared enriched in inflammatory genes (19) .
Our present work sought to expand this knowledge of OA epigenetics in order to address 2 major questions unanswered by previous studies. The first was whether regional differences in methylation exist between eroded and intact cartilage within the same joint, which may be linked to disease progression. We hypothesized that many genes and pathways linked to OA would have significant changes in their epigenetic state as the disease progresses. Our second question was whether CpG methylation varies linearly with OA disease activity; we hypothesized that several differentially methylated CpG sites would be highly correlated with histologic score. To address these questions, we performed the largest survey, pathway, and ontological analysis to date of the methylation status of Ͼ485,000 CpG sites throughout the entire genome of paired samples of eroded and intact cartilage obtained from hip joints of 24 OA patients. Additionally, we performed histopathologic modified Mankin scoring (20) and methylation correlation analyses on 12 samples, as well as limited gene expression profiling of selected differentially methylated genes in a subset of 12 samples.
MATERIALS AND METHODS
Samples and nucleic acid isolation. Twenty-four femoral heads were obtained from patients undergoing hip arthroplasty for end-stage primary OA at the McBride Orthopedic Hospital in Oklahoma City. Demographic information about these patients is presented in Supplementary Table 1, available on the Arthritis & Rheumatology web site at http://online library.wiley.com/doi/10.1002/art.38762/abstract. The Institutional Review Boards in all involved institutions approved this study. Full-thickness cartilage samples representing grossly eroded and grossly intact cartilage were obtained from areas of each femoral head, divided into portions for DNA and RNA extraction, and flash-frozen in liquid nitrogen. Additional portions of tissue were collected from 6 femoral heads and placed in 4% paraformaldehyde (Sigma-Aldrich) for subsequent histologic analysis. Samples were then ground using either a mortar and pestle or a cryogenic grinder mill (Spex CertiPrep). DNA was isolated from each sample using a DNeasy kit (Qiagen), and 500 ng was subsequently treated with sodium bisulfite using an EZ-DNA MethylationLightning kit (Zymo Research).
DNA methylation studies. Genome-wide DNA methylation was assessed using the HumanMethylation 450 BeadChip microarray (Illumina), which analyzes the methylation status of Ͼ485,000 methylation sites throughout the genome, covering 99% of RefSeq genes at an average of 17 CpG sites per gene across the 5Ј-UTR, gene promoter regions, first exon, gene body, and 3Ј-UTR, and covering 96% of University of California, Santa Cruz-defined CpG islands and their flanking regions. Following bisulfite treatment, DNA from each sample was loaded onto chips and processed by the Oklahoma Medical Research Foundation Genotyping Core Facility. This array includes a variety of both sample-independent and sample-dependent controls, which were evaluated in each chip.
Histologic examination. Following fixation, samples were embedded in paraffin and slides were cut for both hematoxylin and eosin and Safranin O staining. Two pathologists (MES, ACA) scored each case using the modified Mankin scale, and a mean score was determined (see Supplementary Statistical analysis. Chips were imaged and data were extracted using the GenomeStudio methylation module, version 2011.1 (Illumina). The percent methylated cytosines at each CpG site (␤) was calculated as the ratio of methylated probe signal to total locus signal intensity and defined within a range of 0 to 1 by GenomeStudio; average ␤ values were then compared. Differentially methylated CpG sites were defined as those having a differential methylation score Ն͉21͉, corresponding to a P value of less than 0.01 after adjusting for multiple testing using GenomeStudio's built-in false discovery rate function, which employs a Benjamini and Hochberg procedure with ␣ ϭ 0.05. A second requirement was a mean methylation difference (⌬␤) Ն 0.15 (15%) between the 2 groups. CpG sites with a known single-nucleotide polymorphism located within or 10 bp from the 3Ј-end of the probe were excluded. The locations of particular CpG sites within regulatory regions were defined by GenomeStudio, including CpG islands as well as North (5Ј) and South (3Ј) Shores (N-Shores and S-Shores) and North (5Ј) and South (3Ј) Shelves (N-Shelves and S-Shelves), which represent ϳ2 kb surrounding CpG islands and shores, respectively. Location statistics were calculated using the Yates' correction of a chi-square distribution P value of a 2 ϫ 2 contingency table.
Gene ontology analyses. Functional properties, networks, pathways, and upstream regulators enriched in differentially methylated genes were assessed using the Ingenuity Pathways Analysis (IPA) system (Ingenuity Systems) using the Ingenuity Knowledge Base reference set. Direct and indirect relationships were calculated, and experimentally observed relationships were included; P values less than or equal to 0.05 were considered significant. In addition to the standard upstream regulator analysis, microRNAs (miRNAs) overrepresented among differentially methylated genes were identified by IPA using experimentally demonstrated and predicted miRNA-messenger RNA (mRNA) interactions or binding sites from TarBase, miRecords, and TargetScan databases, as well as peer-reviewed miRNA research articles as curated by Ingenuity Systems staff.
Histologic correlation. In the 12 samples with histopathologic scores, CpG methylation at each site was compared to the modified Mankin score. HOXA5 , and HOXA9 were determined by traditional bisulfite Sanger sequencing and subsequent analysis using the ESME software package (Epigenomics) (21), a method we have used extensively in the past (10). We found a high level of correlation between methylation values reported by the Illumina array and those found by this traditional sequencing method (R 2 ϭ 0.84; n ϭ 193) (see Supplementary Figure 1 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/ art.38762/abstract).
Differential methylation confirmation. Finally, to confirm differential methylation of 3 CpG sites among the most highly differentially hypomethylated genes identified by the Illumina array (cg19348484: FURIN; cg04915566 and cg01519261: RUNX1), custom, commercial pyrosequencing analysis was performed (EpigenDx) on a subset of 12 eroded and 12 intact cartilage samples.
RESULTS
Significant differential CpG methylation between eroded and intact OA cartilage. We identified a total of 550 differentially methylated CpG sites in grossly eroded cartilage samples compared with intact samples. Of these, 378 (69%) were hypomethylated and 172 (31%) were hypermethylated (Table 1 and Figure 1 ), corresponding to 390 distinct, known genes and nearby genomic regions. Differentially methylated sites were concentrated in enhancers, 50% observed among hypomethylated sites (P Ͻ 0.0001) and 37% observed among hypermethylated CpGs (P ϭ 0.002), as compared to 21% expected for both for the assay. Enhancers are segments of regulatory genomic sequence that may exert effects at remote locations to control both spatial and temporal gene expression. Additional enrichment was noted in the N-Shore regions of CpG islands among hypomethylated CpGs (9% observed compared to 5% expected; P ϭ 0.03) and within gene bodies among hypermethylated CpGs (68% observed compared to 36% expected; P Ͻ 0.0001) (see Supplementary Table 4 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.38762/ abstract).
Differential methylation among several genes implicated in OA pathology. The most hypomethylated CpG site in our analysis was in the 5Ј-UTR of FURIN, encoding a proprotein convertase. Previous studies have found FURIN to be significantly overexpressed in OA cartilage (22) , which is consistent with our methylation findings; however, we did not find evidence of overexpression in our samples (mean Ϯ SEM 2.4 Ϯ 0.8 relative units for eroded cartilage versus 1.5 Ϯ 0.3 relative units 
Ϫ38
Gene body --* ⌬␤ ϭ absolute difference in methylation value between sample groups (␤ eroded Ϫ ␤ intact ); FDR ϭ false discovery rate; UCSC ϭ University of California, Santa Cruz; 5Ј-UTR ϭ 5Ј-untranslated region; N ϭ North; NA ϭ not applicable; S ϭ South; TSS 200 ϭ within 200 bp of transcription start site.
for intact cartilage; P ϭ 0.29) ( Figure 2D ). Significant hypomethylation of this CpG site was independently confirmed by pyrosequencing analysis (cg19348484: ⌬␤ ϭ 0.35, P ϭ 1.7 ϫ 10
Ϫ4
) (see Supplementary Figure 2 , available on the Arthritis & Rheumatology web site at http:// onlinelibrary.wiley.com/doi/10.1002/art.38762/abstract).
The second and sixth most hypomethylated CpG sites were within the 5Ј-UTR of RUNX1, previously identified as differentially methylated in OA. We identified 6 additional hypomethylated sites associated with this gene. Counterintuitively, we found an ϳ50% reduction of expression in eroded cartilage (1. Figure  2G ). Significant hypomethylation of 2 RUNX1 CpG (Figure 2H ).
We identified 8 significantly hypomethylated CpG sites in both the body and within 1,500 bp of the transcription start site (TSS) of DLX5, which plays an important role in chondrogenesis and induces the expression of Runx2 (23) . Our studies indicate that DLX5 is epigenetically poised for expression; however, we did not find a significant difference in expression among samples (4.9 Ϯ 1 relative units for eroded cartilage versus 9.9 Ϯ 1 relative units for intact cartilage; P ϭ 0.07) ( Figure 2B ). We found hypomethylation of 1 CpG site within 1,500 bp of the TSS of HTRA1, a member of the high-temperature requirement family of serine proteases which is elevated in synovial fluid and cartilage of OA patients, and we found overexpression of HTRA1 (7.4 Ϯ 1.4 relative units for eroded cartilage versus 1.4 Ϯ 0.4 relative units for intact cartilage; P ϭ 0.002) ( Figure  2E ), strongly suggesting epigenetic activation. Next, we found 2 significantly hypermethylated CpGs within an island and S-Shore associated with NFATC1, a member of the nuclear factor of activated T cells family which functions as a key suppressor of OA, but we did not find evidence for differential expression in our samples (2.13 Ϯ 0.4 relative units for eroded cartilage versus 1.87 Ϯ 0.4 relative units for intact cartilage; P ϭ 0.76) ( Figure 2F) .
Among structural genes, we found hypermethylation of 2 CpG sites within the body of COL11A2, which encodes the pro-␣2(XI) chain of type XI collagen that maintains the diameter and cohesive strength of cartilage matrices (24) . Furthermore, we identified a 75% reduction in COL11A2 expression in eroded cartilage, which corroborates a functional consequence of this hypermethylation (3.7 Ϯ 1 relative units for eroded cartilage versus 15 Ϯ 0.8 relative units for intact cartilage; P ϭ 0.0002) (Figure 2A) . FGFR2 is involved in chondrocyte differentiation. We found 12 hypermethylated CpGs within 200 bp of the TSS or within the N-Shelf of CpG islands associated with FGFR2. Concordantly, we found a 77% reduction in gene expression (0.43 Ϯ 0.2 relative units for eroded cartilage versus 1.8 Ϯ 0.2 relative units for intact cartilage; P ϭ 0.01) ( Figure 2C ).
Differential methylation among many OA susceptibility genes. We next turned our attention to the methylation status of known OA susceptibility genes. We reduced the absolute methylation difference (⌬␤) threshold requirement for differential methylation from 15% to 10% and found 83 CpG sites among 24 of 64 recently reported susceptibility genes, including (Table 2) .
ADAM12, ACAN, CALM1, CLIP, COL1A1, COL2A1, COL9A2, COL11A2, DOT1L, ENPP1, ESR1, FRZB, FTO, IGF2, IL10, IL1RN, ITGA6, LRP5, MMP3, NCOR2, SERPINA3, SUPT3H, TGFB1, and TP63
Gene ontology and network analysis show that differentially methylated genes cluster among known OA effectors. Next, we performed IPA to determine networks, diseases, pathways, biologic functions, and upstream regulators associated with differentially methylated genes. The most highly enriched network included many genes known to be associated with OA, and centered on SMAD3 ( Figure 3A) . A second network involved several genes associated with OA, including HTRA1, NFATC1, and DLX5 ( Figure 3B ). The top overrepresented biologic functions were "development of cardiovascular system" (P ϭ 3.45 ϫ 10 Ϫ8 ; n ϭ 44 genes) and "development of connective tissue" (P ϭ 9.79 ϫ 10
Ϫ6
; n ϭ 18 genes). Interestingly, 5 of the top 7 most highly overrepresented functional categories involved angiogenesis or cardiovascular development. Immunologic functions were overrepresented as well, with "cell movement of T lymphocytes" (P ϭ 5.39 ϫ 10
; n ϭ 14 genes). The top canonical pathway identified was "regulation of interleukin-2 expression in activated and anergic T lymphocytes" (P ϭ 1.05 ϫ 10
Ϫ3
) (see Supplementary Table 5 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/ 10.1002/art.38762/abstract), highlighting both the importance of inflammation in OA pathology and the likely contribution of epigenetic control mechanisms to OA inflammation.
Overrepresentation of transforming growth factor ␤ (TGF␤) and both known and novel miRNA associations among differentially methylated genes, as demonstrated by upstream regulator analysis. Differentially methylated genes were predicted to have a number of miRNA interactions (see Supplementary Table 6 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.38762/ abstract); the top 3 included miR-128 (P ϭ 4.48 ϫ 10
Ϫ13
; n ϭ 50 genes), the MMP regulator miR-27a (P ϭ 4.15 ϫ 10 Ϫ12 ; n ϭ 43 genes), and the chondroblast survival regulator miR-9 (P ϭ 9.20 ϫ 10
Ϫ10
; n ϭ 48 genes). The most enriched non-miRNAs included the protooncogene ERG (P of overlap ϭ 9.49 ϫ 10 Ϫ6 ; n ϭ 11 genes), the growth factor and OA effector TGFB1 (P of overlap ϭ 4.40 ϫ 10
Ϫ5
; n ϭ 44 genes), the cytokine TNF (P of overlap ϭ 1.27 ϫ 10
Ϫ4
; n ϭ 41 genes), the inducer of MMPs ELK1 (P of overlap ϭ 4.65 ϫ 10
; n ϭ 5 genes), and the TGF␤-induced signaling molecule SMAD2 (P of overlap ϭ 5.48 ϫ 10 Ϫ4 ; n ϭ 6 genes). High correlation of several CpG sites with disease activity as measured by histopathologic score. Finally, to study whether CpG methylation may be correlated with OA progression, we performed histologic modified Mankin scoring on a subset of our samples (20, 25) . These had a variety of grades of OA; all eroded portions had significantly higher scores than intact portions within the same joint, confirming our gross categorizations (see Supplementary Table 2 , avail- * Requirements for inclusion were P Ͻ 0.01 and absolute methylation difference (⌬␤) Ն 0.10. OA ϭ osteoarthritis (see Table 1 for other definitions). We identified 20 CpG sites that met criteria for significance (Table 3 ) (correlations for the 4 most highly Figure 3C ).
DISCUSSION
We performed the first genome-wide DNA methylation analysis of matched eroded and intact cartilage tissue from hips of 24 OA patients, offering a unique insight into the progression of this disease. This experimental design reflects a significant departure from previous methylation studies, which have used control tissue from disease-free cadaveric donors or patients undergoing surgical procedures correcting femur neck fractures, a population enriched in osteoporosis, a practice that may introduce its own set of confounding epigenetic aberrations. Our approach lessens the impact of unknown confounders and reduces the contribution of unknown genetic variation, but it does have inherent limitations. In particular, our study design is unable to detect methylation changes from early disease or differential methylation present throughout the affected joint, as most of our intact cartilage samples had at least minimal damage as evidenced by modified Mankin scores Ͼ0, which may explain the lack of concordance of our findings with a previously reported knee OA genomewide methylation study that used disease-free controls.
Our experiments revealed several significant findings. First, we found evidence for differential methylation among several genes that are intimately involved in OA and among many with associated differential expression, pointing toward a contribution of epigenetic dysregulation to their pathogenic effects. Second, we found moderate differential methylation among more than one-third of known OA susceptibility genes, suggesting DNA methylation as an alternate method for disruption of their activity. Third, network analysis identified pathways enriched in differentially methylated genes with hubs of known OA effectors, and upstream regulator analysis was highly enriched in OAlinked TGFB1 and ERG as well as in both known and novel miRNAs. Finally, we described several CpG sites whose methylation levels were highly correlated with the histopathologic disease severity score, highlighting the continuous nature of at least some epigenetic marks during disease progression.
We identified 550 CpGs that met our criteria for differential methylation (Table 1 and Figure 1 ) (see Supplementary Table 7 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/ doi/10.1002/art.38762/abstract), associated with 312 unique genes, enriched in enhancers, previously hypothesized as alternatives to promoters for epigenetic regulatory control (26) . Only 3 of these genes were identified Table 1 for other definitions).
2812 JEFFRIES ET AL in a previous knee OA genome-wide methylation study (RUNX1, MGAT1, and WIPF1) (19) . We observed novel differential methylation of several genes involved in OA pathogenesis. Hypomethylated FURIN processes a variety of ADAMTS molecules involved in OA collagen degradation (27) . Indeed, inhibition of furin and other like enzymes is sufficient to significantly reduce collagen breakdown and the levels of active collagenase and MMP-2 in vitro (28) . Furin is also required to process TGF␤1 into its active form (29) , and inhibition of TGF␤1 in subchondral bone attenuates OA (30) .
The relationship between RUNX1 and OA is unclear. A previous knee OA genome-wide DNA methylation study identified RUNX1 as the most hypomethylated CpG site in its assay (19) . Despite its epigenetic status, several studies have demonstrated, counterintuitively, that RUNX-1 is underexpressed in OA chondrocytes (31,32), which we confirmed in our RT-PCR analysis. Further study to characterize other epigenetic modifications of the local chromatin environment (e.g., histone methylation/acetylation) is needed to explore these seemingly contradictory findings. Our analysis also identified hypomethylation of RUNX2, which is known to be overexpressed in OA chondrocytes. RUNX-2 cooperates with CCAAT/enhancer binding protein ␤ to drive MMP-13, a major contributor to cartilage degradation (33, 34) . Further, it is directly downstream of the MEK/ERK pathway (35, 36) and immediately upstream of the MMP ADAMTS-5, both of which have wellestablished roles in OA (37) . This hypomethylation corroborates previously observed overexpression of RUNX-2 in OA chondrocytes (34), although we did not find this among our samples.
We also identified hypomethylation of DLX5, which induces the expression of RUNX-2 in animal models (23) . We found both hypomethylation and overexpression of HTRA1, which is elevated in synovial fluid and cartilage explants from OA patients (38, 39) where it functions to degrade multiple components of the articular cartilage matrix (38, 40) , releasing MMPs. These findings strongly suggest an epigenetic role in its pathologic expression. NFATC1, a key suppressor of OA, was hypermethylated. This is consistent with previous studies showing reduced NFATC1 expression in OA cartilage (41), although we did not find a significant change in expression among our samples.
Among structural genes, we found evidence for hypermethylation and reduced expression of the type XI collagen gene COL11A2. Mutations within COL11A2 have been associated with a number of hereditary osteochondrodysplasias, featuring severe, early-onset OA degenerative joint disease (42) . Interestingly, polymorphisms within COL11A2 have been associated with spinal degenerative disease, but not with OA of the hip or knee (43) . Our results suggest epigenetically mediated silencing with effects similar to those caused by genetic mutation. Hypermethylated FGFR2 is also implicated in several genetic craniosynostosis syndromes and is significantly up-regulated during chondrocyte differentiation (44) . In addition, we found significant reduction in FGFR2 expression. These both suggest examples of epigenetically mediated gene alterations mimicking the phenotype of genetic mutations.
Upon initial review, among 64 genetic susceptibility loci validated in 3 recent meta-analyses (7-9), only 3 associated genes (CLIP, COL11A2, and SUPT3H) met criteria for differential methylation. This was likely due to our strict 15% absolute methylation difference requirement, as relaxing this to 10% revealed a remarkable 83 differentially methylated CpG sites among 24 known OA susceptibility genes. This is striking; by this definition, 38% of the known OA susceptibility genes are associated with at least moderate differential DNA methylation (Table 2) . Much like findings for COL11A2 and FGFR2, this suggests that gene disruption leading to disease phenotype may be accomplished either by genetic mutation or epigenetic dysregulation.
IPA revealed that many differentially methylated genes are present in networks known to be involved in OA. The first network identified centered on SMAD3 (itself hypomethylated in our assay), which functions in a highly correlated manner with TGF␤ to maintain articular cartilage (45) (Figure 3A) . A second network included the aforementioned NFATC1, HTRA1, and DLX5. Akt was central in this network, which upregulates MMP production through hypoxia-inducible factor 2␣ and NF-B and contributes to OA pathology ( Figure 3B ) (46) . Both of these networks demonstrate likely indirect effects of differentially methylated genes on known OA effector pathways.
Several IPAs identified upstream regulators as enriched among differentially methylated genes (see Supplementary Table 5 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/ doi/10.1002/art.38762/abstract). Of the 5 top miRNAs, 2 have previously reported associations with OA. These are miR-9, overexpressed 8-fold in OA cartilage (47) , and miR-27a, linked to MMP-13 and insulin-like growth factor binding protein 5 in vitro (48) . The other miRNAs we found enriched among differentially methylated genes are novel associations, and these deserve further study. The most highly enriched non-miRNA upstream regulator we identified was the Ets-related gene ERG, which plays a crucial role in cartilage development through chondrocyte growth and hypertrophy regulation (49) . Also highly enriched was TGFB1, present in 11% (n ϭ 44) of differentially methylated genes mapped, with a P value of 4.4 ϫ 10 Ϫ5 . Zhen et al recently described chondroprotection in an anterior cruciate ligament destabilization mouse model of OA via both TGF␤ receptor knockout and anti-TGF␤ antibody treatment of subchondral bone, which was linked to a reduction in mesenchymal stem cell recruitment to the site of injury (30) . These observed effects might be influenced by epigenetic dysregulation of TGF␤-targeted genes.
Finally, we identified several CpG sites whose methylation status was highly correlated with the histologic grade of OA (Table 3 ) (see Supplementary Figure  3 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.38762/ abstract). All of these genes, with the exception of FGF23, represent novel associations with OA. Interestingly, none met our criteria for significant differential methylation in the larger categorical experiment. IPA identified a single associated network that contained 15 of the 17 differentially methylated genes; the key hubs of this network are known OA-and inflammationassociated proteins and transcription factors including Mapk, TNF, and Pkc ( Figure 3C ). This finding of a strong association of methylation with histologic grade gives hope for the future identification of biomarkers of disease activity and provides evidence that epigenetic contributions to OA pathology may exist along a continuum, rather than being a binary phenomenon.
In summary, our present set of experiments constituted the first genome-wide DNA methylation study in hip OA using a unique method comparing eroded and intact cartilage from the same joint. We demonstrated a number of differentially methylated CpG sites, several of these associated with OA-implicated genes, and we offered the first description of differential methylation among OA susceptibility genes. Furthermore, we identified a number of functional networks highly enriched in differentially methylated genes with well-known OA regulators as hubs. Finally, we offered a novel description of strong correlation between the methylation level of several CpG sites and the histologic grade of OA cartilage, and we found that these associated genes cluster in a single network containing well-known OA hubs. These findings offer further evidence that OA is a complex disease involving complex genomic-epigenomic interactions.
